



13 January 2020

ASX Announcement

Australian Clinical Trials Manager to replace European role

13 January 2020 – Race Oncology Limited (ASX: RAC) today announced that the Company’s consulting contract with Dr Samar Al-Behaisi (Chief Medical Officer and VP of Medical Affairs) would conclude on 20 March 2020. In line with the Company’s new strategy, Race is now recruiting an Australian-based head of its clinical research activities.

The Europe-based role commenced in May 2018 and was driven by the focus, at that time, on generating named patient usage in Europe. However, RAC recently announced a new strategic direction, called the ‘5 Path’ clinical strategy, which is focused on clinical development programs in Australia and US.

“With the new strategy and the Chief Scientific Officer based in Australia, we decided to place our senior clinical management role in Australia,” said RAC CEO, Peter Molloy. “We thank Samar for her positive contribution over the last two years and wish her all the best.”

RAC is currently advertising for a Senior Clinical Research Manager based in Australia to oversee all Australian trials that are planned under the 5-Path strategy.

- ENDS -

About Race Oncology (RAC: ASX)

Race Oncology is a specialty pharmaceutical company whose business model is to pursue later-stage drugs in the cancer field that have been overlooked by big pharma. The company’s first drug is Bisantrene, a chemotherapy agent that was the subject of more than 40 clinical studies during the 1980s and 1990s before the drug was abandoned. Bisantrene has compelling clinical data in acute myeloid leukaemia (AML) as well as other cancers including breast and ovarian. Race is seeking to gain US FDA approval for Bisantrene. Bisantrene is the subject of three recently granted US patents owned by Race and has been awarded US Orphan Drug designation and a ‘Rare Paediatric Disease’ (RPD) designation that entitles Race to a valuable Priority Review Voucher (PRV) upon approval.

Release authorised by:

Peter Molloy, Managing Director
plmolloy@raceoncology.com

Media contact:

Heidi Cuthbert
+61 411 272 366
heidi.cuthbert@multiplier.com.au